SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and strong delivery guidance, fueling community excitement over a potential short squeeze and comparisons to past EV growth rallies, despite facing immediate price resistance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is highly volatile amid conflicting reports surrounding the Strait of Hormuz, ranging from US intelligence indications of potential Iranian mining to a retracted government claim of naval escorts. This geopolitical uncertainty, coupled with political statements about the Iran conflict nearing its end, is fueling community debate over market manipulation and global oil supply stability.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending with soaring investor enthusiasm, driven by its recently secured EPA, UK, and EU regulatory clearances for its ultra-pure graphene and strong anticipation of major commercial contracts and a NASDAQ uplisting. The community widely views the company as a potential leader for the "graphene age," poised to revolutionize diverse sectors from defense to AI data centers.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending significantly ahead of its earnings call, with market participants heavily debating its aggressive AI data center investments, the associated debt, and the status of key cloud partnerships. The community is focused on whether its substantial cloud growth and AI backlog can offset concerns about capital expenditures, positioning this event as a critical read for the broader AI infrastructure sector.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is seeing extreme volatility, with community discussion centered on conflicting reports about the Strait of Hormuz
Aquickly deleted government claim of a navy escort was followed by intelligence suggesting Iran is deploying mines, leading to sharp market swings and widespread accusations of manipulation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility driven by rapidly changing geopolitical headlines from the Middle East, with the community actively debating market manipulation tactics as the index demonstrates surprising resilience through sharp recoveries.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics is seeing massive community interest and extreme price swings, with chatter focusing on a potential short squeeze and its clinical-stage pipeline for rare diseases, catalyzed by recent news regarding its Phase 2 trial and unusual pre-market volatility.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is experiencing high volume and robust discussion following strong Q4 earnings, which showed accelerated sales of its flagship rare disease drug, MIPLYFFA. The market is re-evaluating ZVRA's potential as it transitions to a profitable commercial-stage company, with many in the community anticipating further upside ahead of potential European approval.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech Inc. (CITR) is generating strong trading momentum and community buzz due to its presentation at the iAccess Alpha conference, showcasing its differentiated fire-retardant wood technology, with its low share float driving speculation of a significant re-rating if commercial traction continues.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following news that the FDA lifted its Complete Response Letter for Deramiocel and set a new PDUFA date. The community is buzzing with optimism for an accelerated approval of its Duchenne Muscular Dystrophy therapy, further propelled by the imminent departure of a controversial FDA official.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RLFTF
Even the professor on the Discord group pages, was dismayed with the FDA’S nod on this one.... 
https://www.theguardian.com/us-news/2022/dec/29/biogen-fda-alzheimers-aduhelm-congressional-report
Still it&#39;s big pharma, so no real surprises there then...  However I do recall that Sami Said previously stated that they had seen some remarkable changes in cognition in patients who had recieved his lab made small batches of AVIPTADIL...

Happy New year to all of us long suffering investors, I think that if we can finally manufacture a good stable long shelf life product, from all the collated data, possibly a new tie up with Nephron too..  That there is a lot of runway for AVIPTADIL in the future...  GLTA LONGS

Terence P McReynolds

andrew keary

Wong3

Robert Allen Sajdak

US drug regulators failed to follow their own guidance and practices when they approved the controversial Alzheimer's drug Aduhelm, a congressional report said on Thursday. The US food and drug administration's (FDA) process of approval, it said, had been "rife with irregularities", and the FDA's interactions with maker Biogen had been "atypical".

the Guardian

FDA under fire over approval of Alzheimer's drug Aduhelm

StockTwits For Android 

Relief Therapeutics Holding AG


Even the professor on the Discord group pages, was dismayed with the FDA’S nod on this one.... 



Still it's big pharma, so no real surprises there then...  However I do recall that Sami Said previously stated that they had seen some remarkable changes in cognition in patients who had recieved his lab made small batches of AVIPTADIL...

Happy New year to all of us long suffering investors, I think that if we can finally manufacture a good stable long shelf life product, from all the collated data, possibly a new tie up with Nephron too..  That there is a lot of runway for AVIPTADIL in the future...  GLTA LONGS

Healthier Choices Management Corp

Saddle Ranch Media Inc

@Ajk222 

https://www.researchgate.net/profile/Orhan-Korkmaz/publication/329279755_Vasoactive_Intestinal_Peptide_Decreases_b-Amyloid_Accumulation_and_Prevents_Brain_Atrophy_in_the_5xFAD_Mouse_Model_of_Alzheimer&#39;s_Disease/links/5c04538a92851c63cab623d3/Vasoactive-Intestinal-Peptide-Decreases-b-Amyloid-Accumulation-and-Prevents-Brain-Atrophy-in-the-5xFAD-Mouse-Model-of-Alzheimers-Disease.pdf